ReviewBMJ (Clinical research ed.)2023
Efficacy, safety, and tolerability of antidepressants for pain in adults: overview of systematic reviews.
Review in BMJ (Clinical research ed.), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 51 papers, 6 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
51 citing papers in PubMed, 6 syntheses or guidelines pooled it, 91 citations in OpenAlex.
- Efficacy and Harms of Opioid Analgesics for Acute Pain: Overview of Systematic Reviews and Meta-analyses.Drugs · 2026Pooled it
- Beyond Depression: The Role of Antidepressants in Managing Chronic Temporomandibular Disorders. A Systematic Review.Journal of oral rehabilitation · 2025Pooled it
- Investigating pain-related medication use and contribution to polypharmacy in adults with intellectual disabilities: a systematic review.BMC medicine · 2024Pooled it
- Efficacy and safety of antidepressants for pain in older adults: A systematic review and meta-analysis.British journal of clinical pharmacology · 2024Pooled it
- Pooled it
- Preventive drug treatments for adults with chronic migraine: a systematic review with economic modelling.Health technology assessment (Winchester, England) · 2024Pooled it
- Phase 1 randomized trial of HS-10353, a novel GABA(A) positive allosteric modulator for treatment of major depressive disorder.BMC medicine · 2026Trial
- Quality of life, pain and use of analgesic, anxiolytic and antidepressant medication, in people living in care homes.Age and ageing · 2024Trial
- Distinct parafascicular neuronal ensembles mediate the sensory and affective dimensions of trigeminal neuralgia.The Journal of clinical investigation · 2026Article
- Changes in Pregabalin Dispensing to Australians with Workers' Compensation Claims for Low Back Pain Following the Listing of Pregabalin on the Pharmaceutical Benefits Scheme.Journal of occupational rehabilitation · 2026Article
- Self-Efficacy as a Central Mediator of Pain, Function, and Depression: Insights of a Cross-Sectional Analysis of Depersonalized Data from the German Pain e-Registry.Journal of clinical medicine · 2026Article
- Review
- Mirtazapine for the treatment of irritable bowel syndrome: A systematic review.World journal of methodology · 2026Article
- Opioid overdose associated with concomitant use of hydrocodone and selective serotonin reuptake inhibitors.BMC medicine · 2025Article
- Clinical Outcomes of Repeated Sodium Polynucleotide Injections in Knee Osteoarthritis: Large-Scale, Retrospective Cohort Study.Journal of clinical medicine · 2025Article
- Visualizing Real-World Pain Treatment Pathways in Chronic Disease: A Sequence-Based Analysis of Polypharmacy in Systemic Lupus Erythematosus.ACR open rheumatology · 2025Article
- Locus Coeruleus MR Measured Signal Intensity in Fibromyalgia Relative to Healthy Controls.European journal of pain (London, England) · 2025Article
- EEG Spectral Analysis in Chronic Pain During Rest and Cognitive Reasoning.Sensors (Basel, Switzerland) · 2025Article
- Understanding pain heterogeneity in osteoarthritis patients: a narrative review.Frontiers of medicine · 2025Review
- Virtual Reality for Patients With Chronic Musculoskeletal Pain and Disability: An Umbrella Review of Systematic Reviews.Health science reports · 2025Review
Corrections and comments
- Commented on by
- Commented on by
Authors and funding
9 authors at 5 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo provide a comprehensive overview of the efficacy, safety, and tolerability of antidepressants for pain according to condition.
designOverview of systematic reviews. DATA SOURCES: PubMed, Embase, PsycINFO, and the Cochrane Central Register of Controlled Trials from inception to 20 June 2022. ELIGIBILITY CRITERIA FOR SELECTING STUDIES: Systematic reviews comparing any antidepressant with placebo for any pain condition in adults. DATA EXTRACTION AND SYNTHESIS: Two reviewers independently extracted data. The main outcome measure was pain; for headache disorders it was frequency of headaches. Continuous pain outcomes were converted into a scale of 0 (no pain) to 100 (worst pain) and were presented as mean differences (95% confidence intervals). Dichotomous outcomes were presented as risk ratios (95% confidence intervals). Data were extracted from the time point closest to the end of treatment. When end of treatment was too variable across trials in a review, data were extracted from the outcome or time point with the largest number of trials and participants. Secondary outcomes were safety and tolerability (withdrawals because of adverse events). Findings were classified from each comparison as efficacious, not efficacious, or inconclusive. Certainty of evidence was assessed with the grading of recommendations assessment, development, and evaluation framework.
results26 reviews (156 unique trials and >25 000 participants) were included. These reviews reported on the efficacy of eight antidepressant classes covering 22 pain conditions (42 distinct comparisons). No review provided high certainty evidence on the efficacy of antidepressants for pain for any condition. 11 comparisons (nine conditions) were found where antidepressants were efficacious, four with moderate certainty evidence: serotonin-norepinephrine reuptake inhibitors (SNRIs) for back pain (mean difference -5.3, 95% confidence interval -7.3 to -3.3), postoperative pain (-7.3, -12.9 to -1.7), neuropathic pain (-6.8, -8.7 to -4.8), and fibromyalgia (risk ratio 1.4, 95% confidence interval 1.3 to 1.6). For the other 31 comparisons, antidepressants were either not efficacious (five comparisons) or the evidence was inconclusive (26 comparisons).
conclusionsEvidence of efficacy of antidepressants was found in 11 of the 42 comparisons included in this overview of systematic reviews-seven of the 11 comparisons investigated the efficacy of SNRIs. For the other 31 comparisons, antidepressants were either inefficacious or evidence on efficacy was inconclusive. The findings suggest that a more nuanced approach is needed when prescribing antidepressants for pain conditions. SYSTEMATIC REVIEW REGISTRATION: PROSPERO CRD42022311073.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.